Viatris

VTRSApproved

Viatris is one of the world's largest generic and specialty pharmaceutical companies, created through the transformational merger of Mylan and Pfizer's Upjohn business. The company operates across four key pillars: generics, complex generics, biosimilars, and established brands, with a mission to empower people worldwide to live healthier at every stage of life. Viatris maintains a global manufacturing footprint with facilities across multiple continents and has established itself as a leader in access to medicines worldwide.

Market Cap

$15.2B

Employees

35,000-40,000

Focus

Biotech

VTRS · Stock Price

USD 13.20+2.01 (+17.96%)

Historical price data

AI Company Overview

Technology Platform

Global pharmaceutical development and manufacturing platform focused on generics, complex generics, biosimilars, and established brand medicines with advanced drug delivery systems and formulation science capabilities.

Pipeline Snapshot

247

247 drugs in pipeline, 41 in Phase 3

Drug	Indication	Stage
Imiquimod + Diclofenac	Actinic Keratosis	Approved
Sildenafil	Erectile Dysfunction Following Radical Prostatectomy	Approved
Revefenacin + Tiotropium + Revefenacin Placebo + Tiotropium Placebo	Chronic Obstructive Pulmonary Disease	Approved
Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fl...	Seasonal Allergic Rhinitis	Approved
Azelastine hydrochloride + fluticasone propionate nasal spray + Placebos + fluti...	Seasonal Allergic Rhinitis	Approved

FDA Approved Drugs

ERMEZANDAApr 29, 2022

PRETOMANIDNDAAug 14, 2019

YUPELRINDANov 9, 2018

Opportunities

Viatris has significant growth opportunities in biosimilars, emerging markets expansion, and complex generics development.

The company's global platform positions it well to capitalize on upcoming patent cliffs and increasing demand for affordable medicines worldwide.

Risk Factors

Key risks include intense pricing pressure in generic markets, regulatory complexities across global markets, and ongoing integration challenges from the Mylan-Upjohn merger.

Competition from other generic manufacturers and potential patent litigation also present ongoing challenges.

Competitive Landscape

Viatris competes against major generic pharmaceutical companies like Teva and Sandoz, as well as branded pharmaceutical companies in established medicine markets. The company differentiates through its global scale, diverse portfolio spanning generics to complex products, and strong presence in both developed and emerging markets.

Publications

Pipeline

247

FDA Approvals